Price$15.60+1.99 (+14.66%)
2026-03-052026-06-08
News · 26 weeks46+75%
2025-12-142026-06-07
Mix2890d
- Insider17(61%)
- Other5(18%)
- SEC Filings4(14%)
- Earnings2(7%)
Latest news
25 items- INSIDERDirector Huennekens R Scott was granted 2,890 shares (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Fischer Frank M was granted 2,890 shares, increasing direct ownership by 0.49% to 598,067 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Geiger Uri was granted 2,890 shares, increasing direct ownership by 19% to 17,748 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Kumar Rakhi was granted 2,890 shares, increasing direct ownership by 15% to 22,050 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Ryan Renee was granted 2,890 shares (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Andrade Lisa was granted 2,890 shares (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,255 shares, decreasing direct ownership by 0.89% to 140,436 units (SEC Form 4) to satisfy withholding tax4 - NeuroPace Inc (0001528287) (Issuer)
- PRNeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations-- --NeuroPace to engage neurosurgeon community through clinical education, product feedback sessions, and hands-on booth demonstrations-- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive neu
- PRNeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care-- First in a suite of planned NeuroPace AI tools designed to deliver deeper data insights, support clinical outcomes and further enhance efficiency of RNS therapy -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace's broader AI platform strategy, leveraging the world's only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed. ECoG Assistant: Treatment Insights Simplified ECoG Assistant is the first in a suite of planned NeuroPace
- INSIDERCHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 0.79% to 141,691 units (SEC Form 4) to cover taxes4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 358 shares, decreasing direct ownership by 0.68% to 52,385 units (SEC Form 4) to satisfy withholding tax4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERChief Financial Officer Williams Patrick F. was granted 16,820 shares, increasing direct ownership by 32% to 68,670 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Morrell Martha was granted 5,460 shares, increasing direct ownership by 12% to 52,743 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Becker Joel was granted 45,880 shares, increasing direct ownership by 47% to 142,817 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.SCHEDULE 13G/A - NeuroPace Inc (0001528287) (Subject)
- SECSEC Form 10-Q filed by Neuropace Inc.10-Q - NeuroPace Inc (0001528287) (Filer)
- SECNeuropace Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NeuroPace Inc (0001528287) (Filer)
- PRNeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance--Total revenue of $22.1 million-- -- Raises full year 2026 guidance to $99 million to $101 million, up from $98 million to $100 million previously-- --Assumes 21% to 23% growth in core RNS® revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy (IGE) indication expansion-- --Continues to expect IGE contribution following potential NAUTILUS PMA-Supplement (PMA-S) approval in mid-2026-- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. First Quarter 2026 Highl
- PRNeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2026 after market close on Tuesday, May 12, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessing a live webcast of the event here. Individuals interested in participating in the call via telephone may access the call by dialing + 1 (800) 715-9871 and referencing Conference ID 8467256. The webcast will be archived on the company's inve
- PRNeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026— Published 3-year Post-Approval Study results show 82% median seizure reduction in drug-resistant focal epilepsy — — American Academy of Neurology (AAN) presentation featured 12- and 18-month NAUTILUS data, the first randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) — — Growing body of high-quality clinical evidence reinforces the RNS System's differentiated position across focal and generalized epilepsy — NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the publication of 3
- SECSEC Form DEFA14A filed by Neuropace Inc.DEFA14A - NeuroPace Inc (0001528287) (Filer)
- SECSEC Form DEF 14A filed by Neuropace Inc.DEF 14A - NeuroPace Inc (0001528287) (Filer)
- PRNeuroPace to Present at the 25th Annual Needham Virtual Healthcare ConferenceNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual Needham Virtual Healthcare Conference at 1:30pm ET (10:30am PT) on Tuesday, April 14, 2026. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for thirty days following the presentation in the Events & Presentations section of NeuroPace's Investor website at https://investors.neuropace.com. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medical device company focu
- INSIDERSEC Form 4 filed by Morrell Martha4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERSEC Form 4 filed by Geiger Uri4 - NeuroPace Inc (0001528287) (Issuer)
NPCE FAQ
7 questionsWhat does Neuropace Inc. do?
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in...Where does NPCE stock trade?
Neuropace Inc. (NPCE) is listed on NASDAQ.What sector and industry is NPCE in?
Neuropace Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Neuropace Inc. go public?
Neuropace Inc. (NPCE) completed its IPO in 2021.What are analysts saying about NPCE?
Neuropace Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1800.00 price target on 2025-05-28. Recent price targets range from $600.00 to $2200.00.What companies are similar to NPCE?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare NPCE side-by-side with any of them on Quantisnow.How can I track NPCE on Quantisnow?
Quantisnow aggregates Neuropace Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NPCE to receive live email and push alerts on every new disclosure.